A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
Phase 1
Completed
- Conditions
- cMET-dysregulated Advanced Solid Tumors
- Interventions
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 37
- Registration Number
- NCT02520752
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Emory University School of Medicine/Winship Cancer Institute SC-2, Atlanta, Georgia, United States
A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients
Phase 2
Completed
- Conditions
- Primary Biliary Cholangitis
- First Posted Date
- 2015-08-06
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT02516605
- Locations
- 🇬🇧
Novartis Investigative Site, Newcastle upon Tyne, United Kingdom
Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort
Phase 4
Completed
- Conditions
- COPD
- Interventions
- Drug: Salmeterol/fluticasone 50/500 microgrammesDrug: QVA149 110/50 micrograms
- First Posted Date
- 2015-08-06
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT02516592
- Locations
- 🇹🇷
Novartis Investigative Site, Yenisehir/Izmir, Turkey
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
- First Posted Date
- 2015-08-04
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 64
- Registration Number
- NCT02515331
- Locations
- 🇨🇭
Novartis Investigative Site, Lausanne, Switzerland
Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome
Phase 1
Withdrawn
- Conditions
- Primary Sjögren's Syndrome
- Interventions
- Drug: VAY736 lower doseDrug: VAY736 higher dose
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02495129
First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement
Phase 1
Completed
- Conditions
- Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-07-08
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT02491281
- Locations
- 🇺🇸
Novartis Investigative Site, Phoenix, Arizona, United States
Efficacy and Safety Study of QVA149 in COPD Patients
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Umeclidinium/vilanterolDrug: Placebo (umeclidinium/vilanterol)Drug: Placebo (QVA149)
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 357
- Registration Number
- NCT02487446
- Locations
- 🇺🇸
Novartis Investigative Site, Tacoma, Washington, United States
Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Umeclidinium/vilanterolDrug: Placebo (QVA149)Drug: Placebo (umeclidinium/vilanterol )
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 355
- Registration Number
- NCT02487498
- Locations
- 🇺🇸
Novartis Investigative Site, Greenfield, Wisconsin, United States
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
Phase 2
Completed
- Conditions
- External Genital Warts
- Interventions
- Drug: Investigational Treatment
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT02482428
- Locations
- 🇺🇸
Novartis Investigative Site, Arlington Heights, Illinois, United States
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
Phase 2
Completed
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Other: PlaceboBiological: QGE031Biological: Omalizumab
- First Posted Date
- 2015-06-22
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 382
- Registration Number
- NCT02477332
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom